Trial reportDiabetes care2026
Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.
Rodolfo J Galindo, Bobak Moazzami, Amany Gerges, Ina Flores, Giuliana Arevalo, Limin Peng, Ian H de Boer, Katherine R Tuttle, Guillermo E Umpierrez
Abstract readRandomized Controlled Trial
In one paragraphTrial report in Diabetes care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Rodolfo J GalindoDivision of Endocrinology, University of Miami Miller School of Medicine, Miami, FL.ORCID 0000-0002-9295-3225 Bobak MoazzamiDivision of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Amany GergesDivision of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Ina FloresDivision of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Giuliana ArevaloDivision of Endocrinology, University of Miami Miller School of Medicine, Miami, FL.
Limin PengDepartment of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA.
Ian H de BoerKidney Research Institute and Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA.ORCID 0000-0003-1571-7592 Katherine R TuttleKidney Research Institute and Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA.ORCID 0000-0002-2235-0103 Guillermo E UmpierrezDivision of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, GA.ORCID 0000-0002-3252-5026 Funding
OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository CoreOT2HL161847 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GROSS, RACHEL SHARON, HORWITZ, LEORA · 2021 to 2025
$651.0MTransform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0MImplementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1MConProject-002U2CDK114886 · NIDDK · UNIVERSITY OF WASHINGTON · PI MCCLELLAND, ROBYN LEAGH · 2017 to 2021
$21.0MTraining Program in Clinical & Translationa Research in Human Glomerular DiseaseU54DK083912 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KRETZLER, MATTHIAS · 2009 to 2023
$20.3MTranslational Research Core - Engagement and Behavior ChangeP30DK111024 · NIDDK · EMORY UNIVERSITY · PI Mohammed Kumail Ali · 2016 to 2026
$13.4MCureGN-Penn PCCU01DK100846 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI LAWRENCE B. HOLZMAN · 2019 to 2026
$8.3MPrediction of Chronic Kidney Disease by Simulation Modeling to Improve the Health of Minority PopulationsR01MD014712 · NIMHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BUI, ALEX, NICHOLAS, SUSANNE B · 2020 to 2023
$1.5MDeveloping statistical analysis and prediction tools for continuous glucose monitoring (CGM) use in hospitalized patients with diabetesR01DK136023 · NIDDK · EMORY UNIVERSITY · PI Limin Peng · 2024 to 2026
$1.1MUse of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease(ESRD) Patients with Type 2 DiabetesK23DK123384 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALINDO, RODOLFO · 2020 to 2024
$934kPharmaco-epidemiology of diabetes in patients with end-stage kidney diseaseR03DK138255 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALINDO, RODOLFO · 2024 to 2025
$230kNCATS NIH HHS UL1 TR002319NCATS NIH HHS UL1 TR002378NHLBI NIH HHS OT2 HL161847NIDDK NIH HHS K23 DK123384NIDDK NIH HHS K23DK123384-03NIDDK NIH HHS P30 DK111024NIDDK NIH HHS R01 DK136023NIDDK NIH HHS R03 DK138255NIDDK NIH HHS U01 DK100846NIDDK NIH HHS U2C DK114886NIDDK NIH HHS U54 DK083912NIMHD NIH HHS R01 MD014712
6 · The paper itselfAbstract
objectiveThere is a need for improved glycemia monitoring tools for people with type 2 diabetes (T2D) and end-stage kidney failure (ESKF). RESEARCH DESIGN AND
methodsThis prospective, randomized, crossover trial compared the efficacy of real-time continuous glucose monitoring (rtCGM) with capillary blood glucose (CBG) testing in adults with T2D and ESKF undergoing hemodialysis. The primary outcome was percentage of time below range (%TBR) <70 mg/dL.
resultsThe %TBR <70 mg/dL was not significantly different between groups (mean 1.17% ± 1.8 vs. 1.29% ± 2.7; P = 0.28). Compared with CBG testing, percentage time in range (%TIR) was higher (63.4% ± 24 vs. 54.5% ± 23) and mean glucose lower (173.6 ± 37 vs. 187.7 ± 38 mg/dL) after the rtCGM intervention, while percentage time above range (%TAR) >180 mg/dL (35.3% ± 25 vs. 44.3% ± 23) and >250 mg/dL decreased (12.3% ± 15 vs. 18.8% ± 19) (all P ≤ 0.01).
conclusionsIn adults with T2D and ESKF undergoing hemodialysis, TBR was minimal and not influenced by rtCGM use. Compared with CBG testing, %TIR and %TAR improved during the rtCGM intervention. Future studies are needed to confirm the benefits of rtCGM in this population.
Indexed as
Blood GlucoseDiabetes Mellitus, Type 2Kidney Failure, ChronicRenal DialysisAgedContinuous Glucose MonitoringCross-Over StudiesFemaleHumansMaleMiddle AgedProspective StudiesBlood Glucose
Identifiers
PMID42360278
PMCPMC13493348
What Socratic holds
Textmetadata
Read underepoch 390